Our Mission...
is to improve the quality of health service delivery and reduce the burden of disease and disability in the United States and elsewhere by carrying out broadly based research and education activities involving the translation of innovative medical research into practice

PUBLICATIONS

2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004

2004

Haddow JE, Knight GJ, Palomaki GE, McClain MR, Pulkkinen AJ: The reference range and within-person variability of thyroid stimulating hormone (TSH) during the first and second trimesters of pregnancy.  J Med Screen, 11:170-174, 2004.

Lambert-Messerlian G, Halliday J, Williams J, Cain R, Msall ME, Palomaki GE, Canick JA: Effect of folic acid fortification on prevalence of neural tube defects in Rhode Island J Med Screen, 11:106-107, 2004.

McClain MR, Palomaki GE, Haddow JE: Is first trimester measurement of sex hormone binding globulin a possible screening test for gestational diabetes?  Am J Obstet Gynecol, 190:1808-1809, 2004.

Palomaki GE:  Prenatal screening for cystic fibrosis: An early report card (editorial).  Genet Med, 6:115, 2004.

Palomaki GE, FitzSimmons SC, Haddow JE: Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population.  Genet Med, 6:405-414, 2004.

Palomaki GE, Knight GJ, Roberson MM, Cunningham GC, Lee JE, Strom CM, Pandian R:  Invasive trophoblastic antigen (hyperglycosylated human chorionic gonadotropin) in second-trimester maternal urine as a marker for Down syndrome: preliminary results of an observational study on fresh samples.  Clin Chem, 50:182-189, 2004.

Palomaki GE, Neveux LM, Knight GJ, Haddow JE, Pandian MR: Maternal serum invasive trophoblastic antigen (ITA) as a screening marker for Down syndrome during the second trimester.  Clin Chem, 50:1804-1808.

Pandian RJ, Cole LA, Palomaki GE:  Second-trimester maternal serum invasive trophoblast antigen: a marker for Down syndrome screening.  Clin Chem, 50:1433-1435, 2004.

Ritchie RF, Palomaki GE, Neveux LM, Naolotskaia O:  Reference distributions for complement proteins C3 and C4: a comparison of a large cohort to the world’s literature.  J Clin Lab Anal, 18:9-13, 2004.

Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TM, Craig WY: Reference distributions for complement proteins C3 and C4: a practical, simple and clinically relevant approach in a large cohort.  J Clin Lab Anal, 18:1-8, 2004.

Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TM, Craig WY: Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort.  J Clin Lab Anal, 18:139-152, 2004.

Ritchie RF, Palomaki GE, Neveux LM, Naolotskaia O:  Reference distributions for alpha2-macroglobulin: a comparison of a large cohort to the world’s literature.  J Clin Lab Anal, 18:148-152, 2004.

Ritchie RF, Palomaki GE: Selecting clinically relevant populations for reference intervals.  Clin Chem Lab Med, 42:702-709, 2004.

Watson MS, Cutting GR, Desnik RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, Strom CM, Richards CS, Witt DR, Grody WW: Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.  Genet Med, 6:387-391, 2004.